- Home
- EBMT vs KOD Comparison
EBMT vs KOD Comparison
Compare EBMT & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EBMT | KOD |
|---|---|---|
| Founded | 1922 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.7M | 2.8B |
| IPO Year | 2009 | 2018 |
Fundamental Metrics
Financial Performance| Metric | EBMT | KOD |
|---|---|---|
| Price | $22.46 | $39.52 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $24.00 | ★ $35.43 |
| AVG Volume (30 Days) | 37.7K | ★ 609.0K |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.55% | N/A |
| EPS Growth | ★ 53.23 | N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.00 | N/A |
| P/E Ratio | $43.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.11 | $3.33 |
| 52 Week High | $23.95 | $47.84 |
Technical Indicators
Market Signals| Indicator | EBMT | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 56.35 | 45.87 |
| Support Level | $21.59 | $39.37 |
| Resistance Level | $22.72 | $46.72 |
| Average True Range (ATR) | 0.71 | 3.07 |
| MACD | -0.01 | -1.13 |
| Stochastic Oscillator | 41.61 | 21.07 |
Price Performance
Historical ComparisonAbout EBMT Eagle Bancorp Montana Inc.
Eagle Bancorp Montana Inc operates as a bank holding company. It provides loan and deposit services. The company focuses on residential loans, commercial real estate loans, commercial loans, consumer loans, and home equity loan products. The bank also offers deposit accounts which include checking, savings, money market, individual retirement accounts, and certificates of deposit accounts. It is a diversified lender with a focus on residential mortgage loans, commercial real estate mortgage loans, commercial business loans, agricultural loans, and second mortgage/home equity loan products.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.